XOMA Royalty (XOMA) Other Non-Current Assets (2010 - 2026)
XOMA Royalty's (XOMA) quarterly Other Non-Current Assets came in at $44.3 million in Q1 2026, up 1221.03% year-on-year from $3.4 million in Q1 2025, and down 2.38% quarter-over-quarter from $45.4 million in Q4 2025.
XOMA Royalty (XOMA) Other Non-Current Assets (2010 - 2026) Analysis & Trends
XOMA Royalty has disclosed Other Non-Current Assets across 17 years of filings, most recently posting $44.3 million for Q1 2026.
- Other Non-Current Assets for Q1 2026 came in at $44.3 million, up 1221.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $44.3 million (up 1221.03% YoY), and the FY2025 annual result was $45.4 million, up 1221.71% from the prior year.
- Other Non-Current Assets came in at $44.3 million for Q1 2026 at XOMA Royalty, down from $45.4 million in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $45.4 million in Q4 2025 to a low of $260000.0 in Q2 2022.
- The 5-year median for Other Non-Current Assets is $3.3 million (2025), against an average of $9.5 million.
- Across the five-year window, Other Non-Current Assets plunged 85.67% in 2022 and jumped 2246.15% in 2023, its largest moves.
- XOMA Royalty's Other Non-Current Assets stood at $260000.0 in 2022, then surged by 2246.15% to $6.1 million in 2023, then plunged by 43.74% to $3.4 million in 2024, then soared by 1221.71% to $45.4 million in 2025, then fell by 2.38% to $44.3 million in 2026.
- The last three Other Non-Current Assets figures came in at $44.3 million (Q1 2026), $45.4 million (Q4 2025), and $40.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | 289.41 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 12.40 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 60,000.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.26 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - | 44.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 44.28 Mn |
| Dec 31, 2025 | 45.36 Mn |
| Sep 30, 2025 | 40.08 Mn |
| Jun 30, 2025 | 3.35 Mn |
| Mar 31, 2025 | 3.35 Mn |
| Dec 31, 2024 | 3.43 Mn |
| Sep 30, 2024 | 1.93 Mn |
| Jun 30, 2024 | 6.02 Mn |
| Mar 31, 2024 | 6.02 Mn |
| Dec 31, 2023 | 6.10 Mn |
| Sep 30, 2023 | 411,000.00 |
| Jun 30, 2023 | 283,000.00 |
| Mar 31, 2023 | 260,000.00 |
| Dec 31, 2022 | 260,000.00 |
| Sep 30, 2022 | 260,000.00 |
| Jun 30, 2022 | 260,000.00 |
| Mar 31, 2022 | 301,000.00 |
| Dec 31, 2021 | 301,000.00 |
| Sep 30, 2021 | 301,000.00 |
| Jun 30, 2021 | 128,000.00 |